Pear Therapeutics, Inc. announced the expansion of its collaboration with BrightView Health. This initiative is designed to provide eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET and reSET-O. BrightView, an innovative and patient-focused leader in SUD and OUD treatment, began piloting Pear's products in its centers across six locations in Kentucky and Ohio in early 2022, and intends to expand the initiative across Kentucky, Ohio, Delaware, Massachusetts, and Virginia. BrightView currently has over 80 locations across 8 states.

Substance use disorders are a major public health crisis affecting communities across the country. In 2020 alone, drug overdose deaths in Kentucky increased by nearly 50%, with a state report concluding that isolation caused by the pandemic was a major contributing factor. According to Recovery Ohio's annual review from 2021, 10-15% of all Ohioans have a life history of substance use disorder.

Pear and BrightView are working together to help improve access to care for those affected by this national epidemic. The two products being piloted by BrightView -- reSET and reSET-O -- have been measured in real-world use and their therapeutic content studied in randomized controlled trials, with results published in peer-reviewed medical journals. Additionally, Pear has released publications showing the potential for improved real-world health outcomes and decreased treatment costs for patients using reSET and reSET-O.5-17 reSET is used as a monotherapy for patients 18 years of age or older with substance use disorder and reSET-O is used in combination with buprenorphine-based medication assisted treatment for patients 18 years of age or older with opioid use disorder.

Clinicians receive access to clinical dashboards to inform visits with patients.